G Rastrelli1, L Giovannini2, A E Calogero3, D Gianfrilli4, E Serra5, A Pizzocaro6, V A Giagulli7, G Motta8, G Vancieri9, A Sperandio10, S Andò11, R Selice12, G Luca13, F Cocchiara14, D Canale15, M Maggi16. 1. Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. 2. Endocrinology Unit, Department of Clinical and Molecular Sciences, Umberto I Hospital, Polytechnic University of Marche, Ancona, Italy. 3. Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. 4. Department of Experimental Medicine, La Sapienza University of Rome, Rome, Italy. 5. Department of Internal Medical Sciences, Endocrinology and Metabolic Diseases Unit, Cagliari, Italy. 6. Endocrinology Unit, IRCCS, Humanitas Research Hospital, Rozzano, Milan, Italy. 7. Outpatient Clinic for Endocrinology and Metabolic Diseases, Conversano Hospital, Conversano, Bari, Italy. 8. Department of Medical Sciences, Division of Endocrinology, Diabetology and Metabolism, University of Turin, Turin, Italy. 9. Section of Reproductive Endocrinology and Andrology, Hospital San Giovanni Calibita Fatebenefratelli Isola Tiberina, University of Rome TorVergata, Rome, Italy. 10. Andrology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. 11. Department of Pharmacy, Health and Nutrition Sciences, University of Calabria, Rende, Italy. 12. Department of Molecular Medicine, Section of Clinical Pathology and Center for Human Reproduction Pathology, University of Padova, Via Gabelli 63, 35121, Padua, Italy. 13. Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy. 14. Department of Endocrinological and Medical Sciences, University of Genova, Genoa, Italy. 15. Endocrine Unit, University of Pisa Medical School and Hospitals, Ospedale di Cisanello, Pisa, Italy. 16. Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. mario.maggi@unifi.it.
Abstract
PURPOSE: Management of late onset hypogonadism (LOH) is not homogenous. The aim of the study is to observe the management of patients with low testosterone (T) in highly specialized Italian centres. METHODS: The SIAMO-NOI is an observational longitudinal disease registry for the evaluation of the clinical management of patients with low T levels (total T < 12 nmol/L, calculated free T < 225 pmol/l or already in treatment) in 15 Italian centers members of the Italian Society for Andrology and Sexual Medicine (SIAMS). Clinical and biochemical data were collected for four visits during 12 months of observation. RESULTS: 432 patients (mean age 50.9 ± 14.9 years) were enrolled. Of them, 247 men were receiving androgen therapy, whereas 145 were naive. After the first visit (V0), 80 men started androgen therapy, whereas 55 remained untreated during the entire observation. Younger age [odds ratio (OR) 0.57 (0.35-0.92)], total T < 8 nmol/l [OR 4.69 (1.59-13.81)], complaining at least one sexual symptom [OR 11.55 (2.01-66.35)] and reporting more severe lower urinary tract symptoms [OR 1.27 (1.01-1.60)] predicted starting an androgen therapy. Sixty-four men started therapy immediately after V0 and maintained it until the observation end. When compared to V0, they reported an increase in all the domains of the International Index of Erectile Function-15 (IIEF-15), in the sexual and physical subdomains of the Aging Male Scale as well as in the International Prostate Symptom Score. Conversely, the untreated group reported a significant improvement, although lower than the treated group, only in the erectile function domain of the IIEF-15. CONCLUSIONS: Management of LOH in SIAMS centres is in line with the international guidelines and the newest knowledge about the role of T on prostate health. Androgen therapy is associated with an improvement in all the aspects of sexual life and in the perception of physical strength.
PURPOSE: Management of late onset hypogonadism (LOH) is not homogenous. The aim of the study is to observe the management of patients with low testosterone (T) in highly specialized Italian centres. METHODS: The SIAMO-NOI is an observational longitudinal disease registry for the evaluation of the clinical management of patients with low T levels (total T < 12 nmol/L, calculated free T < 225 pmol/l or already in treatment) in 15 Italian centers members of the Italian Society for Andrology and Sexual Medicine (SIAMS). Clinical and biochemical data were collected for four visits during 12 months of observation. RESULTS: 432 patients (mean age 50.9 ± 14.9 years) were enrolled. Of them, 247 men were receiving androgen therapy, whereas 145 were naive. After the first visit (V0), 80 men started androgen therapy, whereas 55 remained untreated during the entire observation. Younger age [odds ratio (OR) 0.57 (0.35-0.92)], total T < 8 nmol/l [OR 4.69 (1.59-13.81)], complaining at least one sexual symptom [OR 11.55 (2.01-66.35)] and reporting more severe lower urinary tract symptoms [OR 1.27 (1.01-1.60)] predicted starting an androgen therapy. Sixty-four men started therapy immediately after V0 and maintained it until the observation end. When compared to V0, they reported an increase in all the domains of the International Index of Erectile Function-15 (IIEF-15), in the sexual and physical subdomains of the Aging Male Scale as well as in the International Prostate Symptom Score. Conversely, the untreated group reported a significant improvement, although lower than the treated group, only in the erectile function domain of the IIEF-15. CONCLUSIONS: Management of LOH in SIAMS centres is in line with the international guidelines and the newest knowledge about the role of T on prostate health. Androgen therapy is associated with an improvement in all the aspects of sexual life and in the perception of physical strength.
Entities:
Keywords:
Androgen therapy; Late onset hypogonadism; Lower urinary tract symptoms; Predictors; Sexual symptoms; Testosterone
Authors: Artur Carvalho de Araujo; Fernando Gomes da Silva; Fernando Salvi; Monique Carvalho Awad; Eloísio Alexsandro da Silva; Ronaldo Damião Journal: J Sex Med Date: 2009-09-15 Impact factor: 3.802
Authors: Giulia Rastrelli; Emma L Carter; Tomas Ahern; Joseph D Finn; Leen Antonio; Terence W O'Neill; Gyorgy Bartfai; Felipe F Casanueva; Gianni Forti; Brian Keevil; Mario Maggi; Aleksander Giwercman; Thang S Han; Ilpo T Huhtaniemi; Krzysztof Kula; Michael E J Lean; Neil Pendleton; Margus Punab; Dirk Vanderschueren; Frederick C W Wu Journal: J Clin Endocrinol Metab Date: 2015-05-22 Impact factor: 5.958
Authors: Giovanni Corona; Elisa Maseroli; Giulia Rastrelli; Andrea M Isidori; Alessandra Sforza; Edoardo Mannucci; Mario Maggi Journal: Expert Opin Drug Saf Date: 2014-08-19 Impact factor: 4.250
Authors: Steven M Petak; Howard R Nankin; Richard F Spark; Ronald S Swerdloff; Luis J Rodriguez-Rigau Journal: Endocr Pract Date: 2002 Nov-Dec Impact factor: 3.443
Authors: Giovanni Corona; Andrea M Isidori; Jaques Buvat; Antonio Aversa; Giulia Rastrelli; Geoff Hackett; Vincenzo Rochira; Alessandra Sforza; Andrea Lenzi; Edoardo Mannucci; Mario Maggi Journal: J Sex Med Date: 2014-04-04 Impact factor: 3.802
Authors: G Corona; V A Giagulli; E Maseroli; L Vignozzi; A Aversa; M Zitzmann; F Saad; E Mannucci; M Maggi Journal: J Endocrinol Invest Date: 2016-05-30 Impact factor: 4.256